

9 February 2018

R&D Tax Incentive

Resonance Health (ASX: RHT) is pleased to announce that the Company has received an R&D Tax Incentive refund of \$452k for the 2016/2017 financial year.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of their eligible expenditure on research and development over the 12-month period.

The incentive refund results from the Company's ongoing studies on liver and metabolic disease, as well as its newly developed Artificial Intelligence liver iron concentration solution, FerriSmart.

We look forward to providing further R&D updates as work progresses.

Martin Blake

Chairman RHT

For further information please contact:

Alison Laws

Chief Business Development Officer, Resonance Health

E: alisonl@resonancehealth.com P: +61 (0)8 9286 5300